The American College of Obstetricians and Gynecologists (the College) published referral guidelines for women with a pelvic mass that incorporate CA 125. A new multivariate index assay assesses the malignant risk of ovarian tumors before surgery. Our objective was to estimate the performance of the College guidelines with this new multivariate index assay.
T he National Institutes of Health released a consensus statement in 1994 declaring "women with ovarian masses who have been identified preoperatively as having a significant risk of ovarian cancer should be given the option of having their surgery performed by a gynecologic oncologist." 1 There have been numerous publications and guidelines recommending that women with ovarian cancer be under the care of a gynecologic oncologist. [2] [3] [4] [5] [6] [7] [8] Reports indicate that only one third of women with malignant ovarian tumors are referred to gynecologic oncologists for primary surgery. 9, 10 The American College of Obstetricians and Gynecologists (the College) published referral guidelines incorporating menopausal status, physical examination, family history, imaging, and CA 125. 6 These guidelines are useful in predicting advanced-stage ovarian cancer 11, 12 but "perform poorly in identifying early-stage disease, especially in premenopausal women, primarily due to lack of early markers and signs of ovarian cancer." 12 An effective preoperative test, particularly for younger women and early-stage cancers, can have a favorable effect on women's health as survival is better in these populations. 13 This is relevant because only 10% of women with earlystage ovarian cancer receive the recommended staging and treatment. 14 The OVA1 test (multivariate index assay) is a new multivariate diagnostic biomarker assay approved by the U.S. Food and Drug Administration for use in conjunction with physician evaluation to determine whether an ovarian tumor warrants referral to a gynecologic oncologist. Our study objective was to estimate the performance of the College referral guidelines and the effect of replacing CA 125 with the multivariate index assay.
MATERIALS AND METHODS
This multi-institutional trial enrolled patients from 27 primary care and specialty sites across the United States (see the Appendix, available online at http://links.lww.com/AOG/A243). The sites included women's health clinics, obstetrics and gynecology groups, community and university hospitals, gynecologic oncology practices, and health maintenance organization groups. Institutional review board approval was obtained from each site. Participants were recruited by medical staff at each participating institution and represent a consecutive series of patients who met inclusion criteria and agreed to participate in the study. Inclusion criteria included: female patients age 18 years or older, a level of understanding sufficient to give informed consent, agreeable to phlebotomy, an ovarian tumor with planned surgical intervention within 3 months of imaging, and signed informed consent. All ovarian tumors were confirmed with an imaging study (ultrasonography, computed tomography scan, magnetic resonance imaging) before enrollment. Patients were excluded from the study if: age younger than 18, surgical intervention was not planned, declined phlebotomy, or had a malignancy diagnosis in the last 10 years (excepting nonmelanoma skin cancer). Menopause was defined as the absence of menses for at least 12 months or age 50 or older in those patients who were unclear about their menopausal status.
Before surgery, 30 to 50 mL of venous blood was collected into BD plastic vacutainer tubes with clot activators and centrifuged after sitting at 18 -25°C for a minimum of 1 hour and a maximum of 6 hours postphlebotomy. The serum specimens for each patient were pooled and aliquots stored at Ϫ65°C to Ϫ85°C. The specimens were shipped frozen for storage to PrecisionMed International. Biomarker measurements were performed at Quest Diagnostics, Inc. and validated at Johns Hopkins Medical Institutions and Specialty Laboratories. Validation results were submitted to the U.S. Food and Drug Administration. All testing sites were blinded to the clinical and pathologic data. Data analysis was performed by Applied Clinical Intelligence.
The multivariate index assay consists of five immunoassays combined into a single numerical result, including: CA 125-II, transthyretin (prealbumin), apolipoprotein A1, beta 2 microglobulin, and transferrin. Many of these individual biomarkers have been previously reported. [15] [16] [17] The multivariate index assay algorithm cutoffs were derived and validated from two independent serum training sets. The premenopausal and postmenopausal cutoffs were selected to maximize the utility of the composite index over its individual component markers while maintaining a high level of sensitivity and negative predictive value. CA 125-II was measured on the Elecsys 2010 (Roche Diagnostics) and the other four markers were measured on the BN II System (Siemens Healthcare Diagnostics). The OvaCalc software imports, reconciles, and numerically combines the values for each assay and uses the multivariate index assay algorithm to generate an ovarian malignancy risk index score for each individual specimen. The output of the multivariate index assay algorithm is a numeric index between 0.0 and 10.0, with the following clinical report:
• Premenopausal Low probability of malignancy (multivariate index assay less than 5.0) High probability of malignancy (multivariate index assay 5.0 or higher)
• Postmenopausal Low probability of malignancy (multivariate index assay less than 4.4) High probability of malignancy (multivariate index assay 4.4 or higher)
A standard CA 125-II assay (Roche Elecsys) was performed for each patient and the value used in the multivariate index assay algorithm and the CA 125 analysis. The CA 125 clinical cutoff values were chosen in accordance with the College referral criteria 5,11 as more than 200 units/mL for premenopausal women and more than 35 units/mL for postmenopausal women. Additionally, we evaluated the modified College criteria proposed by Dearking (more than 67 units/mL for premenopausal women). 12 The College criteria recommend preoperative consultation with a gynecologic oncologist for one or more of following criteria:
Premenopausal women The revisions to the College guidelines proposed by Dearking include: 1) eliminating the family history of one or more first-degree relatives with ovarian or breast cancer, and 2) lowering the CA 125 threshold in premenopausal women to 67 units/mL. 12 The statistical analysis was stratified based on menopausal status, stage, and pathology diagnosis. Clinically relevant criteria such as sensitivity, specificity, and predictive values were calculated to evaluate the performance of the College and modified College referral criteria. McNemar's 2 test was used to compare the performance of the College guidelines with and without the multivariate index assay. Test performance was calculated for all pelvic malignancies (including epithelial ovarian cancer, nonepithelial ovarian cancer, borderline ovarian tumors, metastases to the ovary, and other nonovarian pelvic malignancies), with respect to menopausal status. Subanalysis was performed in patients with primary ovarian malignancies (epithelial and nonepithelial ovarian cancers) with respect to menopausal status and stage. Ninety-five percent confidence intervals were constructed, and P values were calculated from t tests and Fisher exact test where appropriate. Statistical analysis was performed with SAS 9.1 (SAS Institute Inc.).
RESULTS
Between 2007 and 2008, the study enrolled 590 women with an ovarian mass verified by an imaging study. Of these, 516 were evaluable. Women were excluded from analysis if surgery was either not performed 27 or delayed more than 3 months, 3 pathology report was not available (nϭ26), 26 blood specimen was unusable (nϭ9), 9 physician assessment was not available (nϭ8), 8 or imaging study did not confirm an adnexal tumor (nϭ1). 1 The clinical and pathologic characteristics of all evaluable patients are summarized in Table 1 . More than half of the patients (52%) were enrolled by physicians who were not specialty trained in gynecologic oncology. There were 161 pelvic malignancies in women with a documented ovarian tumor on preoperative imaging. One hundred and fifty one had ovarian malignancies (29%), nine patients had a pelvic malignancy but normal ovarian histology, and one patient had an ovarian tumor of low malignant potential and a synchronous endometrial cancer. There were 355 patients with benign ovarian conditions.
The performance of the College and modified College referral guidelines in all pelvic malignancies are reported in Table 2 . Evaluating all 516 patients, the performance of the Dearking modifications did not differ statistically from the College criteria. When separated by menopausal status, the modified College guidelines were associated with an increase in sensitivity (58 -76%) and decrease in specificity (77-70%) for premenopausal women, and increase in specificity (56 -71%) for postmenopausal women. On univariate analysis, CA 125, ascites, and radiographic evidence of metastatic disease had the highest odds ratio for predicting ovarian cancer (Table 3) .
The multivariate index assay was substituted for CA 125 in the College guidelines and the results are summarized in Tables 4, 5 , and 6. Using McNemar's test, the sensitivity of the College guidelines with the multivariate index assay was significantly higher than the College guidelines ( 2 of 21.5 [dfϭ1], PϽ.001). Compared with the College guidelines, the calculated negative predictive value for the College guidelines with the multivariate index assay also increased, whereas the specificity and positive predictive value decreased (Table 4 ). The improvement in sensitivity and negative predictive value was most notable for premenopausal women. When a subanalysis for primary ovarian malignancy was performed, the College guidelines with the multivariate index assay were more sensitive but less specific for early-stage disease than the original College criteria for premenopausal (Table  5 ) and postmenopausal ( 
DISCUSSION
There is agreement on the importance of early involvement of a gynecologic oncologist in the care of women with ovarian cancer. [2] [3] [4] [5] [6] [7] [8] [9] [10] The challenge is how best to identify tumors at risk for malignancy, particularly in premenopausal women who account for up to 20% of all ovarian cancers. 18, 19 Examination alone is often unreliable. 20, 21 Although several algorithms have been proposed, 5,6,22-28 they either are used infrequently or are ineffective given that only 30 -40% of women with ovarian cancer initially are treated by a gynecologic oncologist.
9,10 Sensible referral guidelines are important to help concentrate ovarian cancer care at centers where surgical expertise improves outcomes. 29 In this multicenter trial, the College guidelines were evaluated in a diverse group of primary care and specialty centers. The sensitivity of the College referral criteria was lower than previously published.
11,12
The predictive values were also lower in this study, which may be a consequence of lower overall cancer prevalence (31% compared with 37%). Considering the Dearking modifications, eliminating family history and lowering the CA 125 threshold for premenopausal women further emphasized the significance of the CA 125 result. In our trial, most patients did not show signs of advanced disease on imaging (8% ascites; 1% metastatic implants). So for all remaining premenopausal women, CA 125 was the only criterion left to determine the risk of malignancy.
The multivariate index assay is approved for use in women scheduled for surgery for an ovarian tumor. This assay combines CA 125 with four additional biomarkers, enhancing its ability to detect malignancy, particularly early-stage cancers. When the multivariate index assay replaces CA 125 in the College guidelines, the new guidelines detect almost 80% of all missed malignancies and more than 90% of missed epithelial ovarian cancers. The high sensitivity in premenopausal women and early-stage cancers is where CA 125 and the College guidelines have underperformed. Identifying these patients for referral is valuable because many are not receiving appropriate surgical staging and treatment. 13, 14 The College guidelines with the multivariate index assay are also effective at detecting advanced disease, where aggressive cytoreductive surgery and chemotherapy improve overall survival. [7] [8] [9] [10] 29 In addition, the College guidelines with the multivariate index assay permit a simplified algorithm for evaluating a pelvic mass. Because menopausal status is incorporated into the multivariate index assay result and family history appears to be of marginal significance, the referral criteria can be simplified (Box 1). The clinical performance of this simplified algorithm is similar to Table 4 , with sensitivity 93%, specificity 40%, positive predictive value 41%, and negative predictive value 93%. Beyond identifying more malignancies, it is not known precisely how the multivariate index assay will affect the referral of patients. Adding the multivariate index assay to the College criteria resulted in a decrease in specificity, which implies that women with nonmalignant tumors may be referred to gynecologic oncologists. In actual practice, lower specificity does not necessarily translate into more benign tumor referrals. The decision to refer a patient is an individualized integration of medical and nonmedical variables. Historically, 12% to 40% of women referred to a gynecologic oncologist have an ovarian malignancy 11, 12, 23 ; thus, current practice demonstrates that more than 60 -80% of referrals are for benign disease. In this trial, the calculated specificity of the College criteria was 68%, yet the number of nonmalignant tumors referred to the gynecologic oncologist was very high. Of the 355 benign ovarian tumors in the study, 72% were referred to a gynecologic oncologist for surgery, including 45% of patients referred despite the belief by the enrolling physician that the tumor was benign. It is possible that the higher negative predictive value of the College guidelines with the multivariate index assay may add enough reassur- ance to deter referral in situations where the clinician is uncertain. One of the strengths of this study is the multicenter design, enrolling a diverse patient population from numerous geographic sites. All study information was collected prospectively and recorded before surgery, including blood, imaging studies, physical examination, and family history. Also, internal biomarker validation was performed at two independent laboratories. A potential limitation of this study is the use of the newer CA 125-II assay rather than the original assay. Today, there are numerous CA 125 and CA 125-II assays which are available and used interchangeably for preoperative evaluations with very similar diagnostic accuracy. 30 The cancer prevalence in this study is similar to previous reports. 11, 12 In a population with lower cancer prevalence, the test performance will have a lower positive predictive value and higher negative predictive value, although sensitivity and specificity will be unaffected.
In conclusion, replacing CA 125 with the multivariate index assay improves the sensitivity and negative predictive value of the College referral guidelines while decreasing specificity and positive predictive value. Using the multivariate index assay in the College guidelines will identify more malignancies before surgery, but further study is needed to determine the effect on patient referral.
